Summit Therapeutics PLC (SMMT) Receives Outperform Rating from Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc. reissued their outperform rating on shares of Summit Therapeutics PLC (NASDAQ:SMMT) in a research report report published on Wednesday. The firm currently has a $28.00 target price on the stock.
SMMT has been the subject of a number of other reports. Zacks Investment Research raised Summit Therapeutics PLC from a hold rating to a buy rating and set a $7.00 price target for the company in a report on Wednesday, September 14th. HC Wainwright initiated coverage on Summit Therapeutics PLC in a report on Friday, September 16th. They issued a buy rating and a $26.00 price target for the company. Canaccord Genuity reaffirmed a buy rating and issued a $14.00 price target on shares of Summit Therapeutics PLC in a report on Friday, September 9th. Needham & Company LLC lifted their price objective on Summit Therapeutics PLC from $22.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday. Finally, Janney Montgomery Scott began coverage on Summit Therapeutics PLC in a research report on Tuesday, June 21st. They issued a buy rating for the company. Six equities research analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus target price of $23.80.
Summit Therapeutics PLC (NASDAQ:SMMT) opened at 13.75 on Wednesday. The company has a 50-day moving average of $7.69 and a 200-day moving average of $7.73. Summit Therapeutics PLC has a 12 month low of $4.26 and a 12 month high of $19.75. The company’s market cap is $169.04 million.
An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Granite Point Capital Management L.P. acquired a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 112,676 shares of the company’s stock, valued at approximately $891,000. Granite Point Capital Management L.P. owned about 0.92% of Summit Therapeutics PLC at the end of the most recent quarter. Institutional investors and hedge funds own 23.43% of the company’s stock.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.